sPLA2 Inhibitor
Phase 1/2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout sPLA2 Inhibitor
sPLA2 Inhibitor is a phase 1/2 stage product being developed by Eli Lilly for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT00034476. Target conditions include Sepsis.
What happened to similar drugs?
9 of 19 similar drugs in Sepsis were approved
Approved (9) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
9
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00034476 | Phase 1/2 | Completed |
Competing Products
20 competing products in Sepsis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Alkaline Phosphatase + Placebo | AM-Pharma | Phase 2 | 25 |
| Drotrecogin alfa (activated) | Eli Lilly | Phase 2 | 35 |
| Meropenem | Pfizer | Approved | 43 |
| Imipenem | Merck | Approved | 39 |
| Cefiderocol | Shionogi | Phase 1 | 29 |
| eritoran tetrasodium + Placebo | Eisai | Phase 3 | 40 |
| E5564 | Eisai | Phase 2 | 35 |
| Drotrecogin Alfa (Activated) + placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin Alfa (activated) | Eli Lilly | Approved | 43 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) + Placebo | Eli Lilly | Phase 3 | 40 |
| Drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin | Eli Lilly | Approved | 43 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| drotrecogin alfa (activated) | Eli Lilly | Approved | 43 |
| AZD9773 (CytoFab) | AstraZeneca | Phase 2 | 35 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD9773 + Placebo | AstraZeneca | Phase 2 | 35 |
| AZD4144 + Placebo | AstraZeneca | Phase 2 | 42 |